GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Astonea Labs Ltd

Astonea Labs H1 FY27 Consolidated Revenue Up 44.6% YoY to ₹95.86 Cr; PAT Rises 153.3%

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 14 Nov 2026, 03:57 PM IST  ·  BSE ID: d18754c6-7769-45fd-801b-c8585ed98cb0
View Original BSE Filing (PDF)
💡
In Simple Terms
Astonea Labs reported strong half-year earnings and approved plans to make Longevity Science Private Limited a subsidiary.
🤖 AI Summary
  • Astonea Labs' Board approved Unaudited Consolidated Financial Results for H1 FY27, with revenue from operations at ₹95.86 crore.
  • Consolidated Profit After Tax (PAT) for H1 FY27 increased to ₹4.82 crore from ₹1.90 crore in H1 FY26.
  • The company approved proposed related party transactions with Longevity Science Private Limited for up to ₹12,00,00,000/- during FY27.
  • Astonea Labs plans to acquire 51% of Longevity Science Private Limited's share capital, making it a subsidiary.
  • The company voluntarily adopted Indian Accounting Standards (Ind AS) effective April 01, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from operations (H1 FY27)
₹95.86 crore
+44.6%
Profit after tax (H1 FY27)
₹4.82 crore
+153.3%
EBITDA (H1 FY27)
₹13.20 crore
+140.7%
Related Party Transactions (FY27)
₹12,00,00,000/-
Debt to equity (30 Sep 2026)
0.79x
Debt to EBITDA (last 12 months, 30 Sep 2026)
2.6x
🏢 How This Affects the Company
📈
Business Impact
Consolidated revenue growth of 44.6% YoY and a new subsidiary acquisition could expand Astonea Labs' market reach and product offerings, particularly in its OTC portfolio and export markets. The company targets ₹215 crore in revenue for FY27 and ₹300 crore or more for FY28.
💰
Financial Impact
Increased PAT margin of 5.0% for H1 FY27 reflects improved profitability. Gross borrowings increased to ₹57.15 crore as of 30 September 2026, leading to a rise in debt to equity ratio to 0.79x from 0.64x, while Debt to EBITDA improved to 2.6x from 3.1x.
⚙️
Operational Impact
Tablet output capacity increased by 35%, and the plant is compliant with revised Schedule M and WHO-GMP, enhancing production capabilities. Regulatory audits and a plant fire caused temporary disruptions, moving some dispatches to Q3 FY27.
⚠️
Risk Impact
The proposed related party transactions with Longevity Science Private Limited, and its subsequent subsidiary status, introduce new business integration and operational risks. An exceptional loss of ₹0.46 crore was incurred due to a plant fire on 27 April 2026.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this specific filing.
👤
Who Is Affected
Existing shareholders will see their holdings impacted by the company's financial performance, with consolidated PAT increasing to ₹4.82 crore. The proposed subsidiary acquisition through 51% share capital subscription may dilute future earnings or offer growth opportunities.
🔍
Management Signal
Management is focused on increasing profitability, expanding capacity, and pursuing strategic acquisitions to drive growth in both domestic and international markets, as evidenced by the Longevity Science Private Limited acquisition plan and ambitious FY27-FY29 revenue targets.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — monitor impact of regulatory audits and plant fire on revenue.
Progress on Longevity Science Private Limited acquisition — confirm completion and integration status.
FY27 full-year results — assess achievement of revenue target of ₹215 crore or more.
MEDIUM RISK Debt to equity ratio increased; exceptional loss from plant fire; new acquisition integration risks.
💡 Investor Takeaway
Astonea Labs reported H1 FY27 consolidated revenue from operations at ₹95.86 crore, up 44.6% YoY, with PAT increasing 153.3% YoY to ₹4.82 crore. The Board approved proposed related party transactions up to ₹12,00,00,000/- for FY27 and plans to acquire 51% share capital of Longevity Science Private Limited.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated revenue from operations for H1 FY27 grew 44.6% YoY to ₹95.86 crore, demonstrating strong top-line performance.
  • Profit After Tax (PAT) for H1 FY27 increased 153.3% YoY to ₹4.82 crore, with PAT margin rising to 5.0%.

⚠️ Concerns

  • Gross borrowings increased to ₹57.15 crore by 30 September 2026, raising the debt to equity ratio to 0.79x from 0.64x in H1 FY26.
  • An exceptional loss of ₹0.46 crore was reported in H1 FY27 due to a plant fire on 27 April 2026.
📅 Company Track Record
Astonea Labs' H1 FY27 consolidated revenue growth of 44.6% YoY to ₹95.86 crore builds on prior reports, including a H1 FY27 consolidated revenue of ₹95.86 crore and PAT up 153.3% YoY noted in a previous filing on November 14, 2026. The company's Board also approved FY26 consolidated results in July 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What were Astonea Labs' consolidated revenue and profit for H1 FY27?
Astonea Labs' consolidated revenue from operations for H1 FY27 was ₹95.86 crore, and Profit After Tax was ₹4.82 crore.
What was the year-on-year growth for Astonea Labs' H1 FY27 consolidated revenue and PAT?
Consolidated revenue from operations for H1 FY27 grew 44.6% YoY, and Profit After Tax increased 153.3% YoY compared to H1 FY26.
Which entity is Astonea Labs planning to acquire as a subsidiary?
Astonea Labs plans to subscribe to 51% of Longevity Science Private Limited's share capital, making it a subsidiary.
What is the approved value for related party transactions with Longevity Science Private Limited for FY27?
The Board approved proposed business transactions with Longevity Science Private Limited for an aggregate value not exceeding ₹12,00,00,000/- during FY27.
What were Astonea Labs' debt to equity and debt to EBITDA ratios as of 30 September 2026?
As of 30 September 2026, Astonea Labs' debt to equity ratio was 0.79x and debt to EBITDA (last 12 months) was 2.6x.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.

Live IPO, GMP and market updates on Telegram

IPO open and close dates, grey market premium moves, subscription figures, allotment and listing days, and the market updates worth knowing about, posted on the channel as they happen.

Join the channel